PLGA-modified polyethylenimine self-assembly nanotechnology for nucleic acid and drug delivery
Embodiments of the invention concern copolymers and nanoparticles for use as delivery agents for one or more agents for therapy for a medical condition of humans and animals. Some of embodiments of the invention provide new reagents for biomedical research in cell culture, animal models and plants, for example. The copolymers comprise PLGA and PEI and, in some embodiments, also comprise 1-(3-aminopropyl)-4-methylpiperazine (APMP), Fc binding peptide and/or antibody. In certain embodiments, APMP-PLGA-PEI, Fc binding peptide/antibody-PLGA-PEI or Fc binding peptide/antibody-APMP-PLGA-PEI nanoparticles comprising one or more therapeutic agents are delivered to an individual in need thereof or used for biomedical research in cell cultures, animal models and plants.
1. A composition comprising:
a copolymer consisting of lactide-co-glycolide and PEI;
wherein single lactide-co-glycolide (LGA) units are each conjugated to primary amines of PEI through an amide linkage;
wherein the w/w ratio of LGA to PEI is 0.5:1 to 5:1; and
at least one therapeutic and/or diagnostic agent selected from the group consisting of a nucleic acid, protein, peptide, small molecule, antigen, vaccine, delivery agent, antibody, and mixtures thereof.
2. The composition of claim 1 , wherein the composition is in the form of a microparticle or a nanoparticle.
3. The composition of claim 1 , wherein the copolymer is chemically conjugated to a linker.
4. The composition of claim 3 , wherein the linker is a polyethylene glycol (PEG) linker.
5. The composition of claim 4 , wherein the PEG linker is Maleimide-PEG-NHS.
6. The composition of claim 3 , wherein the linker is chemically conjugated to Fc binding peptide or antibody for specific delivery.
7. The composition of claim 1 , wherein the nucleic acid is DNA.
8. The composition of claim 7 , wherein the DNA is double stranded, single stranded, or a mixture thereof.
9. The composition of claim 7 , wherein the DNA is an oligonucleotide.
10. The composition of claim 1 , wherein the nucleid acid is RNA.
11. The composition of claim 10 , wherein the RNA is double stranded, single stranded, or a mixture thereof.
12. The composition of claim 10 , wherein the RNA is an oligonucleotide.
13. The composition of claim 10 , wherein the RNA is siRNA, shRNA, miRNA, or a mixture thereof.
14. The composition of claim 1 , wherein the composition is a controlled or sustained release composition.
15. The composition of claim 1 , wherein the diagnostic agent is a labeled diagnostic agent.
16. A composition comprising:
a copolymer consisting of lactide-co-glycolide, PEI, and one compound selected from the group consisting of 1-(3-aminopropyl)-4-methylpiperazine (APMP), 2-(3-aminopropylamino) ethanol, 2-methyl-1,5-diaminopentane, 1-(3-aminopropyl)pyrrolidine, 4-aminophenyl disulfide, and cystamine;
wherein single lactide-co-glycolide units are each conjugated to primary amines of PEI through an amide linkage;
wherein the w/w ratio of LGA to PEI is 0.5:1 to 5:1; and
at least one therapeutic and/or diagnostic agent selected from the group consisting of a nucleic acid, protein, peptide, small molecule, antigen, vaccine, delivery agent, antibody, and mixtures thereof.
17. The composition of claim 16 , wherein the composition is in the form of a microparticle or a nanoparticle.
18. A method of making a composition comprising at least one therapeutic and/or diagnostic agent and a copolymer consisting of lactide-co-glycolide and PEI, the method comprising the steps of:
mixing PLGA and PEI in a solvent to provide a solution comprising a lactide-co-glycolide and PEI copolymer;
adding at least one therapeutic and/or diagnostic agent to the copolymer solution to provide a dispersion; and
isolating the composition comprising at least one therapeutic and/or diagnostic agent and copolymer;
wherein the copolymer comprises single lactide-co-glycolide (LGA) units each conjugated to primary amines of PEI through an amide linkage, and a w/w ratio of LGA to PEI of from 0.5:1 to 5:1.
19. The method of claim 18 , wherein the step of adding at least one therapeutic and/or diagnostic agent to the compolymer solution comprises conjugating the copolymer to a linker that is conjugated to the at least one therapeutic and/or diagnostic agent.
20. A copolymer composition comprising
lactide-co-glycolide and PEI; and
optionally one compound selected from the group consisting of 1-(3-aminopropyl)-4-methylpiperazine (APMP), 2-(3-aminopropylamino) ethanol, 2-methyl-1,5-diaminopentane, 1-(3-aminopropyl)pyrrolidine, 4-aminophenyl disulfide and cystamine;
wherein single lactide-co-glycolide units are each conjugated to primary amines of PEI through an amide linkage; and
wherein the w/w ratio of LGA to PEI is 0.5:1 to 5:1.